Press release
Primary Mediastinal Large B-cell Lymphoma Pipeline: Advancing Innovation with 18+ Companies Developing Cutting-Edge Therapies | DelveInsight
Primary Mediastinal Large B-cell Lymphoma Pipeline
DelveInsight's "Primary Mediastinal Large B-cell Lymphoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Primary Mediastinal Large B-cell Lymphoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Primary Mediastinal Large B-cell Lymphoma drugs, the Primary Mediastinal Large B-cell Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Primary Mediastinal Large B-cell Lymphoma Pipeline Report
• DelveInsight's Primary Mediastinal Large B-cell Lymphoma Pipeline analysis depicts a robust space with 18+ active players working to develop 20+ pipeline drugs for Primary Mediastinal Large B-cell Lymphoma treatment.
• The leading Primary Mediastinal Large B-cell Lymphoma companies include Taizhou HoudeAoke Biomedical, Curocell Inc., Genmab, TCR2 Therapeutics, TG Therapeutics, Inc., Juno Therapeutics, AstraZeneca, Epizyme, Johnson & Johnson, and others are evaluating their lead assets to improve the Primary Mediastinal Large B-cell Lymphoma treatment landscape.
• Key Primary Mediastinal Large B-cell Lymphoma pipeline therapies in various stages of development include LP002, CRC01, Epcoritamab, GEN3009, TC-110 T Cells, TG-1801, JCAR017, Acalabrutinib, Tazemetostat, Ibrutinib, and others.
• In February 2025, Pfizer announced the FDA's approval of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for treating adult patients with certain types of relapsed or refractory large B-cell lymphoma (LBCL).
• In January 2025, Roche announced that it received 510(k) clearance from the U.S. FDA for its VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail, a highly-sensitive in-situ hybridization (ISH) test. The test aids pathologists in distinguishing B-cell malignancies from normal reactive responses to infections, enabling quicker treatment decisions. This follows the assay's CE Mark approval in June 2024.
• In July 2023, Schrödinger announced a study of phase 1 clinical trials for SGR-1505. The aim of this study is to assess the safety and tolerability of SGR-1505 and establish its maximum tolerated dose (MTD) and/or recommended dose (RD).
• In July 2023, Memorial Sloan Kettering Cancer Center announced a study of phase 1 clinical trials for 19(T2)28z1xx TRAC T cell. The aim of this study is to assess the potential of utilizing study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, as a viable treatment option for individuals with relapsed/refractory B-cell lymphoma. Additionally, the researchers will be conducting a safety evaluation of this study therapy, seeking to identify the highest dosage that induces minimal or mild side effects in participants.
Request a sample and discover the recent breakthroughs happening in the Primary Mediastinal Large B-cell Lymphoma pipeline landscape @ https://www.delveinsight.com/report-store/primary-mediastinal-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Primary Mediastinal Large B-cell Lymphoma Overview
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive form of large B-cell lymphoma that originates in the mediastinum. It primarily expresses B-cell surface markers, such as CD19, CD20, CD22, and CD79a. Clinically, PMBCL is characterized by rapidly growing anterior mediastinal masses that may compress surrounding structures. Diagnosis is based on pathological features, imaging, and clinical symptoms. The most commonly used treatment regimens are R-CHOP and R-EPOCH, with radiotherapy benefiting some patients, though it can also cause long-term side effects.
Find out more about Primary Mediastinal Large B-cell Lymphoma medication @ https://www.delveinsight.com/report-store/primary-mediastinal-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Primary Mediastinal Large B-cell Lymphoma Treatment Analysis: Drug Profile
Tazemetostat: Epizyme
Tazemetostat (TAZVERIK), developed by Epizyme, is an EZH2 inhibitor that works by blocking EZH2, which in turn promotes the transcription of genes involved in cell cycle control and terminal differentiation, ultimately inhibiting cancer cell proliferation. TAZVERIK has been approved by the U.S. Food and Drug Administration (FDA) for treating certain patients with epithelioid sarcoma (ES) and follicular lymphoma (FL). The drug received FDA accelerated approval in January 2020 for ES and in June 2020 for FL, based on overall response rate (ORR) and duration of response (DOR).
Key Primary Mediastinal Large B-cell Lymphoma Therapies and Companies
• Tazemetostat: Epizyme
• Odronextamab: Regeneron Pharmaceuticals
• Zilovertamab vedotin: Merck
• CALQUENCE (acalabrutinb): AstraZeneca
• Enzastaurin (DB102): Denovo Biopharma
Learn more about the novel and emerging Primary Mediastinal Large B-cell Lymphoma pipeline therapies @ https://www.delveinsight.com/report-store/primary-mediastinal-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Primary Mediastinal Large B-cell Lymphoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Primary Mediastinal Large B-cell Lymphoma Pipeline Report
• Coverage: Global
• Key Primary Mediastinal Large B-cell Lymphoma Companies: Taizhou HoudeAoke Biomedical, Curocell Inc., Genmab, TCR2 Therapeutics, TG Therapeutics, Inc., Juno Therapeutics, AstraZeneca, Epizyme, Johnson & Johnson, and others.
• Key Primary Mediastinal Large B-cell Lymphoma Pipeline Therapies: LP002, CRC01, Epcoritamab, GEN3009, TC-110 T Cells, TG-1801, JCAR017, Acalabrutinib, Tazemetostat, Ibrutinib, and others.
Dive deep into rich insights for drugs used for Primary Mediastinal Large B-cell Lymphoma treatment; visit @ https://www.delveinsight.com/report-store/primary-mediastinal-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Primary Mediastinal Large B-cell Lymphoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Primary Mediastinal Large B-cell Lymphoma Pipeline Therapeutics
6. Primary Mediastinal Large B-cell Lymphoma Pipeline: Late-Stage Products (Phase III)
7. Primary Mediastinal Large B-cell Lymphoma Pipeline: Late-Stage Products (Phase III)
8. Primary Mediastinal Large B-cell Lymphoma Pipeline: Mid-Stage Products (Phase II)
9. Primary Mediastinal Large B-cell Lymphoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Mediastinal Large B-cell Lymphoma Pipeline: Advancing Innovation with 18+ Companies Developing Cutting-Edge Therapies | DelveInsight here
News-ID: 3952178 • Views: …
More Releases from DelveInsight
Candidiasis Clinical Trials Analysis 2025: Oral Agents, Next-Generation Echinoca …
DelveInsight's "Candidiasis - Clinical Trials Analysis, 2025" examines an active clinical landscape addressing both mucosal (vulvovaginal) and invasive candidiasis. Unmet needs for safe, oral, and resistance-resilient therapies have driven the development of therapies across multiple modalities - new oral triterpenoids and azoles for recurrent vulvovaginal candidiasis (RVVC), next-generation echinocandins for candidemia/invasive candidiasis, and first-in-class broad-spectrum agents for drug-resistant and systemic infections. Regulatory progress and late-stage trials over the past few…
Necrotizing Enterocolitis Clinical Trials Analysis 2025: Probiotics, HMOs, and R …
DelveInsight's "Necrotizing Enterocolitis (NEC) - Clinical Trials Analysis, 2025" highlights an evolving pipeline aimed at reducing NEC incidence and severity in preterm infants. With NEC remaining a leading cause of neonatal morbidity and mortality, clinical studies are shifting toward microbiome-based prevention, human milk-derived biologics, and regenerative approaches.
Probiotic regimens containing Bifidobacterium and Lactobacillus strains are showing consistent efficacy in lowering NEC rates and mortality, driving wider adoption in NICUs. Parallel trials…
Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and …
DelveInsight's "Brain Hemorrhage - Clinical Trials Analysis, 2025" surveys an active acute-care landscape focused on reducing hematoma expansion, limiting secondary injury, and improving functional recovery after intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Trials increasingly pursue rapid hemostatic agents, targeted neuroprotectants, and device-based minimally invasive clot evacuation to shorten disability and lower mortality.
Hemostatic and anti-expansion strategies (reversal agents, factor concentrates, and novel transferrable hemostats) aim to stabilize patients early and…
Cachexia Clinical Trials Analysis 2025: Metabolic Modulators, Anabolic Therapies …
DelveInsight's "Cachexia - Clinical Trials Analysis, 2025" examines a diverse development landscape targeting the complex metabolic, inflammatory, and neurohormonal drivers of cancer- and disease-related wasting. Given cachexia's strong association with poor survival, treatment intolerance, and reduced quality of life, trials increasingly measure both anabolic endpoints (lean body mass, muscle strength) and patient-centered outcomes (physical function, fatigue, appetite).
Late-stage and registration-enabling programs span ghrelin agonists and appetite stimulants, selective androgen receptor modulators…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
